Comorbid pathology of the gastrointestinal tract in psoriasis
A. I. Khavkin,
A. V. Naletov,
E. A. Balakireva,
N. A. Marchenko,
A. R. Alnajazhra,
A. K. Dzhabarova,
Yu. V. Kotova https://doi.org/10.31146/2949-4664-apps-2-3-10-14
Abstract
Psoriasis is a chronic inflammatory immune-mediated disease associated and often coexisting with another chronic inflammatory pathology associated with impaired immune response. Immuno-inflammatory diseases of the gastrointestinal tract are recorded with high frequency in patients with psoriasis. The data obtained from the studied literature confirm the connection between psoriasis and inflammatory bowel diseases, celiac disease, non-alcoholic fatty liver disease. The presence of common pathogenetic links, side effects from ongoing psoriasis treatment methods, indicates the need for diagnostic alertness regarding concomitant pathology of the digestive tract in patients with psoriasis. Thus, the presence of comorbid gastroenterological pathology in patients with psoriasis indicates the importance of an interdisciplinary approach in the treatment of these patients.
About the Authors
A. I. Khavkin
Research Clinical Institute of Childhood of the Ministry of Health of the Moscow Region; Belgorod State Research University
Russian Federation
Russian Federation
A. V. Naletov
M. Gorky Donetsk State Medical University
Russian Federation
Russian Federation
E. A. Balakireva
Belgorod State Research University
Russian Federation
Russian Federation
N. A. Marchenko
M. Gorky Donetsk State Medical University
Russian Federation
Russian Federation
A. R. Alnajazhra
Belgorod State Research University
Russian Federation
Russian Federation
A. K. Dzhabarova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Yu. V. Kotova
Research Clinical Institute of Childhood of the Ministry of Health of the Moscow Region
Russian Federation
Russian Federation
References
1. Rendon A., Schäkel K. Psoriasis pathogenesis and treatment.Int J Mol Sci. 2019; 20 (6): 1475. doi: 10.3390/ijms20061475.
2. Armstrong A.W., Read C. pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020; 323 (19): 1945-1960. doi: 10.1001/jama.2020.4006.
3. Amin M., Lee E.B., Tsai T.F., Wu J.J. Psoriasis and co-morbidity. Acta Derm Venereol. 2020; 100 (3): adv00033. doi: 10.2340/00015555-3387.
4. Kamiya K., Kishimoto M., Sugai J., Komine M., Ohtsuki M. Risk factors for the development of psoriasis.Int J Mol Sci. 2019; 20 (18): 4347. doi: 10.3390/ijms20184347.
5. Khavkin A.I., Nalyotov A.V., Marchenko N.A. Inflammatory bowel diseases in children: modern achievements in diagnostics and therapy.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023; 33 (6): 7-15. (In Russ.) doi: 10.22416/1382-4376-2023-33-6-7-15.@@ Хавкин А.И., Налетов А.В., Марченко Н.А. Воспалительные заболевания кишечника у детей: современные достижения в диагностике и терапии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023; 33 (6): 7-15.
6. Khavkin A.I., Nalyotov A.V., Fedulova E.N., Marchenko N.A. Inflammatory bowel diseases in children: diagnostic algorithms and modern therapy strategies. Vopr. dietol. (Nutrition). 2023; 13(3): 32-42. (In Russ.) doi: 10.20953/2224-5448-2023-3-32-42.@@ Хавкин А.И., Налетов А.В., Федулова Э.Н., Марченко Н.А. Воспалительные заболевания кишечника у детей: алгоритмы диагностики и современные стратегии терапии. Вопросы диетологии. 2023. № 13 (23): 32-43.
7. Argollo M., Gilardi D., Peyrin-Biroulet C., Chabot J.F., Peyrin-Biroulet L. et al.Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019; 4 (8): 643-654. doi: 10.1016/S2468-1253(19)30173-6.
8. Antonelli E., Bassotti G., Tramontana M., Hansel K., Stingeni L. et al. Dermatological manifestations in inflammatory bowel diseases. J Clin Med. 2021; 10 (2): 364. doi: 10.3390/jcm10020364.
9. Li Y., Guo J., Cao Z., Wu J. Causal Association between inflammatory bowel disease and psoriasis: a two-sample bidirectional mendelian randomization study. Front Immunol. 2022; 13: 916645. doi: 10.3389/fimmu.2022.916645.
10. Fu Y., Lee C.H., Chi C.C. Association of psoriasis with inflammatory bowel disease: A systematic review and meta-analysis. JAMA Dermatol. 2018; 154 (12): 1417-1423. doi: 10.1001/jamadermatol.2018.3631.
11. Cottone M., Sapienza C., Macaluso F.S., Cannizzaro M. Psoriasis and inflammatory bowel disease. Dig Dis. 2019; 37 (6): 451-457. doi: 10.1159/000500116.
12. Nidegger A., Mylonas A., Conrad C. Paradoxical psoriasis induced by anti-TNF - a clinical challenge. Rev Med Suisse. 2019; 15 (644): 668-671.
13. Vekić-Mužević M., Tomić L., Pondeljak N., Lazić Mosler E. Positivity of celiac disease-specific antibodies and non-celiac hypersensitivity in psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2023; 32 (3): 87-92.
14. Acharya P., Mathur M. Association between psoriasis and celiac disease: A systematic review and meta-analysis. J Am Acad Dermatol. 2020; 82 (6): 1376-1385. doi: 10.1016/j.jaad.2019.11.039.
15. Joel M.Z., Fan R., Cohen J.M. Association between psoriasis and celiac disease: A cross-sectional study in the all of us research program. J Am Acad Dermatol. 2023; 88 (6): 1386-1388. doi: 10.1016/j.jaad.2023.02.004.
16. Brożyna A.A., Slominski R.M., Nedoszytko B., Zmijewski M.A, Slominski A.T. Vitamin d signaling in psoriasis: pathogenesis and therapy.Int J Mol Sci. 2022; 23 (15): 8575. doi: 10.3390/ijms23158575.
17. Buhaș M.C., Gavrilaș L.I., Candrea R., Cătinean A., Mocan A. et al. Gut microbiota in psoriasis. Nutrients. 2022; 14 (14): 2970. doi: 10.3390/nu14142970.
18. Näslund-Koch C., Bennike N.H., Skov L. The importance of diet in psoriasis. Ugeskr Laeger. 2023; 185 (47): V08230535.
19. Dhaher S.A., Hilfi N.Z., Abdullah M.A. Non-alcoholic Fatty Liver Disease Among Iraqi Patients With Psoriasis: A Case-Control Study. Cureus. 2024; 16 (4): e57487. doi: 10.7759/cureus.57487.
20. Ruan Z., Lu T., Chen Y. et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol. 2022; 158 (7): 745-753. doi: 10.1001/jamadermatol.2022.1609.
21. Li H., Su J., Zhu M. et al. Association between psoriasis and non-alcoholic fatty liver disease: a two-sample mendelian randomization study. Clin Cosmet Investig Dermatol. 2023; 16: 3291-3294. doi: 10.2147/CCID.S439115.
22. Torbator K., Poo S., Al-Rubaye T. et al. Whether screening for non-alcoholic fatty liver disease in patients with psoriasis is necessary: a pilot quality improvement project. Cureus. 2022; 14 (5): e24714. doi: 10.7759/cureus.24714.
23. Klujszo E.H., Parcheta P., Witkowska A.B., Krecisz B. Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications. Postepy Dermatol Alergol. 2020; 37 (4): 468-474. doi: 10.5114/ada.2019.83983.
24. Balak D.M.W., Piaserico S., Kasujee I. Non-alcoholic fatty liver disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies. Psoriasis (Auckl). 2021; 11: 151-168. doi: 10.2147/PTT.S342911.
25. Näslund-Koch C., Bojesen S.E., Gluud L.L., Skov L., Vedel-Krogh S. Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: A Mendelian randomization study of 108,835 individuals. Front Immunol. 2022; 13: 1022460. doi: 10.3389/fimmu.2022.1022460.
26. Heitmann J., Frings V.G., Geier A. et al. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network? J Dtsch Dermatol Ges. 2021; 19 (4): 517-528. doi: 10.1111/ddg.14425.
Review
For citations:
Khavkin A.I., Naletov A.V., Balakireva E.A., Marchenko N.A., Alnajazhra A.R., Dzhabarova A.K., Kotova Yu.V. Comorbid pathology of the gastrointestinal tract in psoriasis. Archives of Pediatrics and Pediatric Surgery. 2024;2(3):10-14. (In Russ.) https://doi.org/10.31146/2949-4664-apps-2-3-10-14
Views:
69
Email this article 